GRI Bio, Inc. (GRI)
(Delayed Data from NSDQ)
$0.43 USD
0.00 (1.16%)
Updated May 2, 2024 03:56 PM ET
After-Market: $0.43 0.00 (0.23%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GRI 0.43 0.00(1.16%)
Will GRI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GRI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for GRI
UK earnings, trading statements calendar - next 21 days
Grainger plc Updates Share Capital and Voting Rights
UK earnings, trading statements calendar - next 21 days
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar